292 related articles for article (PubMed ID: 10764422)
1. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
2. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
[TBL] [Abstract][Full Text] [Related]
3. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann TA; Pastan I
Blood; 1999 Nov; 94(10):3340-8. PubMed ID: 10552943
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
Kreitman RJ; Squires DR; Stetler-Stevenson M; Noel P; FitzGerald DJ; Wilson WH; Pastan I
J Clin Oncol; 2005 Sep; 23(27):6719-29. PubMed ID: 16061911
[TBL] [Abstract][Full Text] [Related]
5. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
Kreitman RJ; Stetler-Stevenson M; Jaffe ES; Conlon KC; Steinberg SM; Wilson W; Waldmann TA; Pastan I
Clin Cancer Res; 2016 Jan; 22(2):310-8. PubMed ID: 26350263
[TBL] [Abstract][Full Text] [Related]
6. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.
Onda M; Willingham M; Wang QC; Kreitman RJ; Tsutsumi Y; Nagata S; Pastan I
J Immunol; 2000 Dec; 165(12):7150-6. PubMed ID: 11120846
[TBL] [Abstract][Full Text] [Related]
8. Toxin-labeled monoclonal antibodies.
Kreitman RJ
Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
[TBL] [Abstract][Full Text] [Related]
9. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ; Pastan I
Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
Keppler-Hafkemeyer A; Kreitman RJ; Pastan I
Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Kreitman RJ
Curr Pharm Des; 2009; 15(23):2652-64. PubMed ID: 19689336
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
15. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8548-53. PubMed ID: 10890891
[TBL] [Abstract][Full Text] [Related]
16. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor.
Saito T; Kreitman RJ; Hanada S; Makino T; Utsunomiya A; Sumizawa T; Arima T; Chang CN; Hudson D; Pastan I
Cancer Res; 1994 Feb; 54(4):1059-64. PubMed ID: 8313362
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin.
Pai LH; Wittes R; Setser A; Willingham MC; Pastan I
Nat Med; 1996 Mar; 2(3):350-3. PubMed ID: 8612238
[TBL] [Abstract][Full Text] [Related]
19. Targeting Pseudomonas exotoxin to hematologic malignancies.
Kreitman RJ; Pastan I
Semin Cancer Biol; 1995 Oct; 6(5):297-306. PubMed ID: 8562907
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
